Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy

NCT06359847 is registered in ClinicalTrials.gov with Beijing Scitech-Mq Pharmaceuticals Limited as lead sponsor.

NCT NCT06359847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06359847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
Lead sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2023
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid carcinoma